SCHEMBL182756

SCHEMBL182756

CCCOc1ccc(-c2ccc3nc(N)nc(-c4ccc(OC)c(OC)c4)c3c2)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.44
ADORA1 P30542 2/20 0.44
HSP90AB1 P08238 1/20 0.42
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
MTOR P42345 1/20 0.41
PIK3CG P48736 1/20 0.41
DHFR P00374 2/20 0.41
CSNK2A1 P68400 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
TSHR P16473 1/20 0.39
ERN1 O75460 1/20 0.39
ENPP1 P22413 1/20 0.39
PDE10A Q9Y233 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182850 0.84 DHFR (0.53) ADORA2AADORA1HSP90AB1PIK3CDPIK3CA
SCHEMBL182630 0.84 PIK3CD (0.56) PIK3CDPIK3CAPIK3CBMTORPIK3CG
SCHEMBL183083 0.84 PIK3CD (0.56) PIK3CDPIK3CAPIK3CBMTORPIK3CG
SCHEMBL3334911 0.81 DHFR (0.46) ADORA1PIK3CDPIK3CAPIK3CBMTOR
SCHEMBL1879036 0.80 HSP90AB1 (0.65) ADORA2AADORA1HSP90AB1DHFRL3MBTL1
SCHEMBL182901 0.79 PIK3CA (0.51) ADORA2AADORA1PIK3CDPIK3CAPIK3CB
SCHEMBL183022 0.79 SQSTM1 (0.48) ADORA2AADORA1HSP90AB1PIK3CDPIK3CA
SCHEMBL182810 0.78 PIK3CA (0.49) ADORA2AADORA1HSP90AB1PIK3CDPIK3CA
SCHEMBL3336844 0.78 GAK (0.47) ADORA2AADORA1DHFRL3MBTL1TSHR
SCHEMBL183029 0.78 PIK3CA (0.51) ADORA2AADORA1HSP90AB1PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP claimed
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors NOVARTIS AG 2009-10-15 US claimed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 EP claimed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 WO claimed
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors PDPK1, PI4KA, PIK3CA ADORA2A 1891/4885ADORA1 1951/4885HSP90AB1 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.